Journal article
Using a decline in serum hCG between days 0-4 to predict ectopic pregnancy treatment success after single-dose methotrexate: A retrospective cohort study
M Skubisz, P Dutton, WC Duncan, AW Horne, S Tong
BMC Pregnancy and Childbirth | BMC | Published : 2013
Abstract
Background: The current measure of treatment efficacy of single-dose methotrexate for ectopic pregnancy, is a fall in serum hCG of ≥15% between days 4-7 of treatment, which has a positive predictive value of 93% for treatment success. Two small studies have proposed a fall in serum hCG between days 0-4 after treatment confers similar, earlier prognostic information, with positive predictive values of 100% and 88% for treatment success. We sought to validate this in a large, independent cohort because of the potentially significant clinical implications. Methods: We conducted a retrospective study of women (n=206) treated with single-dose methotrexate for ectopic pregnancy (pre-treatment seru..
View full abstractRelated Projects (1)
Grants
Awarded by Medical Research Council
Funding Acknowledgements
MS is supported by an Australian Postgraduate Award Scholarship through Monash University and a National Health & Medical Research Council (NHMRC) Grant (# 1008276). PD was supported by the Scottish Programme for Clinical Effectiveness in Reproductive Health. CD is supported by a Scottish Senior Clinical Fellowship and AW is supported by a MRC Clinician Scientist Fellowship. ST is supported by a NHMRC Career Development Award (# 490970). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.